Brian Gorman files SEC Form 4 disclosures for OPIANT PHARMACEUTICALS, INC.. They have made 5 open-market trades across 1 company since 2021, most recently 2023-03-02.
CIK 0001813451
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $25K since 2021, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| OPNT | 2,000 | $41K |
Shares reported on the most recent Form 4, priced at the 2023-03-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OPNT | SELL | 2023-01-27 | 2023-01-31 | $20.26 | $9K | +4.5% | N/A | N/A |
| OPNT | SELL | 2023-01-05 | 2023-01-05 | $20.20 | $27K | +0.4% | +2.5% | N/A |
| OPNT | SELL | 2022-07-14 | 2022-07-15 | $11.16 | $8K | -4.6% | +18.9% | -6.3% |
| OPNT | SELL | 2022-06-02 | 2022-06-06 | $13.52 | $16K | -5.2% | -5.6% | -11.5% |
| OPNT | BUY | 2021-09-14 | 2021-09-14 | $19.04 | $25K | +27.9% | +25.9% | +67.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.